ADMA BIOLOGICS, INC.
ADMA · Biotech · Nasdaq · As of 10 Sep 2026
- FundamentalsNot enough data yet
- ValueNot enough data yet
- News flowBalanced
- MomentumWatch
- SafetyStrong
Overall confidence 40/100 — few inputs available yet
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.
Discovery Gap: High (35/100) · Gap confidence 63/100Filings show more traction than the tape reflects.
This month at a glance
AIR Score™ change: 0AIR Score™ held steady this month.
Cycle window9 Sep 2026 → 10 Sep 2026
MoversNothing moved meaningfully this month.
Evidence timeline
- [8-K 2.02] ADMA BIOLOGICS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGARAug 5, 2026 · 8-K
- [8-K 2.02] ADMA BIOLOGICS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGARMay 6, 2026 · 8-K
- [8-K 8.01] ADMA BIOLOGICS, INC. — Other EventsSEC · SEC EDGARMay 4, 2026 · 8-K
- [8-K 8.01] ADMA BIOLOGICS, INC. — Other EventsSEC · SEC EDGARMar 2, 2026 · 8-K
- [8-K 5.02] ADMA BIOLOGICS, INC. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARFeb 20, 2026 · 8-K
- [8-K 2.02] ADMA BIOLOGICS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGARFeb 20, 2026 · 8-K
- [8-K 2.02] ADMA BIOLOGICS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGARJan 12, 2026 · 8-K
- [8-K 2.02] ADMA BIOLOGICS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGARNov 5, 2025 · 8-K
- [8-K 2.02] ADMA BIOLOGICS, INC. — Results of Operations and Financial ConditionSEC · SEC EDGARAug 5, 2025 · 8-K
- [8-K 1.01] ADMA BIOLOGICS, INC. — Entry into a Material Definitive AgreementSEC · SEC EDGARAug 5, 2025 · 8-K
- [8-K 1.02] ADMA BIOLOGICS, INC. — Termination of a Material Definitive AgreementSEC · SEC EDGARAug 5, 2025 · 8-K
- [8-K 2.03] ADMA BIOLOGICS, INC. — Creation of a Material Direct Financial ObligationSEC · SEC EDGARAug 5, 2025 · 8-K
Ask AIR
What would change our view
A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.